News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
New Corin Group plc (US Headquarters) Hip System Wins Nod From FDA Experts; Shares Soar
February 23, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK (CNNMoney.com) -- FDA advisors gave their nod to a new hip resurfacing system from the British company Corin, placing it one step closer to regulatory approval.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
MORE ON THIS TOPIC
Manufacturing
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
October 29, 2026
·
2 min read
·
Nick Paul Taylor
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
·
4 min read
·
Heather McKenzie
Opinion
Biotechs going to market alone must learn to go global
October 28, 2026
·
3 min read
·
Paul Bridges